Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01929707 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3050258 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01929707 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 38 participants.
The verdict
NCT01929707, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and how well the body will handle a single dose of increasing strength of study drug LY3050258. Each participant will receive LY3050258 or placebo once, in each of 2 dosing periods. At least 7 days will pass between doses. This study will last approximately 45 days for each participant. Screening is required within 28 days before the start of the study.
Interventions
- DRUG Placebo
- DRUG LY3050258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2013-08 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01929707
The ClinicalTrials.gov registry entry for NCT01929707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01929707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01929707 about?
NCT01929707 is a clinical study titled "A Study of LY3050258 in Healthy Participants". The main purpose of this study is to evaluate the safety and how well the body will handle a single dose of increasing strength of study drug LY3050258. Each participant will receive LY3050258 or placebo once, in each of 2 dosing periods. At least 7 days will pass between doses. This study will last...
What is the current status of trial NCT01929707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2013-08. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01929707?
The interventions under investigation include: Placebo (DRUG), LY3050258 (DRUG).
Who is sponsoring clinical trial NCT01929707?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.